TenNor Initiated TNP-2198 Phase 1b/IIa Clinical Trials

October 12, 2020/Changchun -- The phase Ib/IIa site initiation meeting of TNP-2198 for the treatment of Helicobacter pylori infection was held at the first affiliated hospital of Jilin University. This is a multiple ascending dose study for safety, pharmacokinetic and preliminary efficacy in volunteers who are infected by H. pylori. Professor Yanhua Ding, Director of the Clinical Center and research team from the hospital, TenNor Therapeutics and CROs attended the meeting.

For more information, please go to：www.tennorx.com